The potential of 4-chloro-ortho-toluidine (4-CloT), an aromatic amine substituted on the ortho-and para-position of the amine function, to induce DNA damage in male Wistar rats was evaluated with the micronucleus test (peripheral blood), Pig-a (peripheral blood), and comet assay (peripheral blood, liver, urinary bladder, jejunum) at several time points. In addition to those markers of DNA damage, ie, gene mutation and clastogenicity, standard hematology, including methemoglobin, histopathology and immunohistochemistry of c-H2AX and Ki-67 in liver, jejunum, and urinary bladder were performed. 4-CloT was administered orally over 28 consecutive days (days 1-28), followed by a 28-day treatment-free (days 29-56), and a second dosing phase of 3 days (days 57-59). 4-CloT showed some effects on the integrity of the DNA as measured by the comet assay in liver and urinary bladder but not in peripheral blood or jejunum. However, for liver and urinary bladder histopathological changes were observed. An increase in the frequency of micronuclei in peripheral blood was seen in parallel to a dose-dependent increase of reticulocytes and methemoglobin. Therefore, impact from a compensatory erythropoiesis on micronucleation cannot be excluded. Interestingly, no increase in the frequency of RET CD59À and RBC CD59À was observed in the Pig-a assay.
4-Chloro-ortho-toluidine (4-CloT) is an aromatic amine substituted both ortho and para to the amine function with a methyl and a chloro group, respectively. The potential of 4-CloT to damage DNA has been reviewed and summarized by the IARC (2010), classifying the compound as a potential human carcinogen (IARC 2A) . While the majority of bacterial reverse mutation tests with 4-CloT did not reveal a mutagenic potential, individual positive responses in single Salmonella typhimurium strains were reported. However, 4-CloT has induced DNA damage in various mammalian cell assays, such as DNA strand breaks, unscheduled DNA synthesis in rat hepatocytes and chromosomal aberrations. Further, it demonstrated DNA binding in rat and mouse liver in vivo as well as induction of mutations in the mouse spot test (Bentley et al., 1986a; Lang, 1984) .
We chose male rats as subjects to further study the effects of 4-CloT on the integrity of the DNA. In particular, the doseresponse relationship for mutant cell induction in reticulocytes (RETs) and red blood cells (RBCs) was analyzed via the Pig-a assay. In addition, DNA strand breakage was assessed in tissues known to be target sites for carcinogenicity of aromatic amines (blood, liver, jejunum, and urinary bladder) (Talaska, 2003; Vineis and Pirastu, 1997) . For a comprehensive data set, potential DNA damage was further evaluated by the micronucleus test in RETs detecting chromosome breaks and maldistribution and by the induction of c-H2AX and Ki-67, as markers of double strand breaks and cell proliferation respectively, in liver. Furthermore, histopathological examination of liver, jejunum, urinary bladder, kidney, and bone marrow was performed.
As with other aromatic amines, 4-CloT has been described to induce the formation of methemoglobin (MetHb) in erythrocytes, due to the oxidization of iron (Fe 2þ to Fe 3þ ). Although hemoglobin (Hb) reversibly binds oxygen, MetHb does not, which can lead to hemolytic anemia. Thus, we measured the induction of MetHb in addition to standard hematology parameters throughout the study. In this study, male Wistar rats were orally dosed with 4-CloT over 28 consecutive days (days 1-28), followed by a treatmentfree period of 28 days (days 29-56), and a second dosing phase of 3 days (days 57-59). DNA damage in different tissues (blood, jejunum, liver, and urinary bladder) was assessed at various time points (days 8, 29, 52, and 59) throughout the study by using the Pig-a assay, micronucleus test and comet assay. Since the comet assay detects strand breaks that may undergo DNArepair over time, a second dosing phase before tissue sampling with dose levels up to the maximum tolerated dose was conducted.
MATERIALS AND METHODS
Chemicals. 4-CloT (CAS 3165-93-3) was purchased from TCI, Tokyo, Japan at a purity of 99.8%. The compound was dissolved in water and aliquots of the dissolved compound were stored frozen. The formulated compound was thawed on the day of administration and was allowed to reach room temperature before being administered.
Animal husbandry, treatment, and dose levels. Male Wistar rats (stock RCCHan: WIST[SPF]), age of about 8 weeks at start of treatment purchased from Harlan, Netherlands were acclimatized for approximately 1 week. The study was performed in conformity with the Swiss Animal Welfare Law (Swiss Animal Welfare Law, 2005) , AALAC and in accordance with Rocheinternal SOPs and guidelines for care and use of laboratory animals.
Three males per cage had ad libitum access to pelleted standard rodent diet and tap water from the domestic supply. Animals were kept in an air conditioned animal room under periodic bacteriological control, at 22 C 6 2 C with monitored 40%-80% humidity, a 12-h light/dark cycle and background radio sound coordinated with light hours. They were assigned randomly to treatment groups, identified by cage card and individually numbered on the base of the tail. 4-CloT was administered orally once per day to 6 animals per dose group at dose levels of 25, 50, 100, 150, 200 , and 250 mg/kg/day over 28 consecutive days (study days 1-28), which was followed by a treatment-free period of 28 days (study days 29-56) and a second dosing period over 3 days (study days 57-59). The latter dosing regimen was primarily introduced to enable combination of the Pig-a assay with the Comet assay and is similar to studies with methyl methanesulphonate (Zeller et al., 2016) and temozolomide (Guerard et al., 2017) . 4-CloT dose levels were chosen based on a previously performed dose range finding experiment, when single animals were administered doses of 100-300 mg/kg/day over 14 consecutive days. At 250 mg/kg/day, no increase in bodyweight was observed, and at 300 mg/kg/day a decrease in body weight was observed from day 4 onwards. Animals treated with 250 and 300 mg/kg/day showed grooming immediately after the administration but no other signs of potential toxicity were observed. Body temperature, determined rectally before and after treatment, did not change significantly (data not shown). Thus, the highest dose for treatment over 28 days was limited to 250 mg/kg/day.
On day 8 of the study, peripheral blood cells from dose levels of 25-250 mg/kg/day were evaluated in the comet assay. No statistically significant increase in %tail intensity (%TI) was observed. It was therefore decided to evaluate tissues with the comet assay on day 59 only for doses of 150 mg/kg/day and higher and that, for the second dosing over 3 days (days 57-59), the low dose animals of 25 mg/kg/day was administered with a new top dose of 350 mg/kg/day, which, based on the rangefinder-experiment, was anticipated to be well tolerated over 3 days. This allowed us to study potential DNA strand breakage in the comet assay similar to performing an acute comet assay experiment. Thus, for the micronucleus (day 8), the Pig-a assay (days 29 and 52), and comet assay in blood (day 8), dose levels of 25-250 mg/kg/day were evaluated and for the comet assay on day 59 (urinary bladder, liver, blood, and jejunum) from 150 to 350 mg/kg/day. Due to the long treatment-free period, it can be assumed that the first treatment period of 28 days had no impact on comet assay results determined at the end of the study. Since exact information on the kinetic of 4-CloT under our testing conditions were not available, tissues for comet assay were sampled approximately 3 h after administration.
Tissue and blood collection. During the in-life phase of the study, blood was sampled sublingually into EDTA tubes from rats under light isoflurane anesthesia. At necropsy, following asphyxiation with CO 2 , blood was taken directly from the heart. For the micronucleus test approximately 50 ml of blood were diluted with anticoagulant (1:7) from which 100 ml were immediately transferred into ultra-cold methanol, mixed and stored at approximately À80 C until further processing for flow cytometric analysis. For the analysis of Pig-a mutant cells approximately 80 ml of blood were diluted with 100 ml anticoagulant and immediately processed according to instructions of the Prototype MutaFlow kit. Blood (50 ml) for the comet assay was directly diluted (1:1) with Hank's Balanced Salt Solution (1ÂHBSS), containing 25 mM EDTA and 10% DMSO, immediately embedded into agarose and further processed for the assay. Blood for hematology and evaluation of MetHb was sampled into EDTA tubes. For practical reasons, blood sampling for both endpoints was split to 2 study days (day 23: animals 1-3 and 26: animals 4-6). A complete blood count was measured using a Sysmex XT-2000iV hematology analyzer (Sysmex, Kobe, Japan). MetHb was determined according to standard method developed by Evelyin and Malloy: Spectrophotometric measurement of blood MetHb is based on maximum absorption at 630 nm, while oxyhemoglobin and the cyanomethemoglobin weakly absorb at this wavelength (Magos, 1960) . The method includes dosage of MetHb and total Hb. Addition of cyanide to one part of 1 hemolysate of a blood sample transforms any present MetHb in cyanomethemoglobin. Absorbance is measured before and after addition of cyanide at 630 nm. The difference between these 2 values is proportional to the amount of formed MetHb. In the other part of this hemolysate, addition of potassium ferricyanide converts all Hb into MetHb. Absorbance measured before and after addition of cyanide gives the total Hb concentration. The results are expressed as a percentage of MetHb compared with total Hb in the sample, in order to adjust interanimal differences in Hb levels.
Liver, urinary bladder, and jejunum for comet assay were sampled during necropsy in 1ÂHBSS, containing 25-mM EDTA and 10% DMSO, and stored on ice until a single cell suspension was prepared (mincing with a pair of tweezers).
For histopathology, liver (left lateral lobe), jejunum (2 longitudinal sections), urinary bladder (one half cut longitudinally), kidneys (1 longitudinal and 1 transversal), and bone marrow (sternum, femur, and tibia) were collected and fixed in 10% neutral buffered formalin for approximately 24 h. All tissue samples were embedded in paraffin, cut at 4 lm and stained with hematoxylin and eosin. Slides were examined under a conventional light microscope.
Micronucleus test. For the micronucleus test (MNT) in peripheral blood, the test methodology was in accordance with requirements of the OECD Guideline 474 (OECD 474, 2014) and current literature (Hayashi et al., 1994; MacGregor et al., 1987; Mavournin et al., 1990) .
The Rat MicroFlow Plus kit from Litron Laboratories (Rochester, New York) was used to perform the micronucleus test in peripheral blood via flow cytometry. After at least 1 week following the fixation of blood specimens in ultra-cold methanol, cells were washed with PBS followed by centrifugation at 400 g for 10 min (Litron Laboratories, 2003) . After removal of the supernatant, cells were resuspended and labeled with fluorescent antibodies against the transferrin receptor indicative of young RET (CD71, FITC, Fluorescein isothiocyanate) and platelets (CD61, PE, Phycoerythrin). RNA was degraded enzymatically; DNA was stained with propidium iodide. Flow cytometric measurement was performed on a Becton-Dickinson LSR II flow cytometer using FACS Diva 8 software. A target of 20 000 RET was interrogated for the presence of micronuclei. Results are given as percentage of RETs and normochromatic erythrocytes (NCEs) containing micronuclei (MN-RET, MN-NCE). All steps were performed on kit-supplied negative-, positive-, and calibration-controls (ie, calibration via malaria-infected rodent blood samples) (Dertinger et al., 2004 (Dertinger et al., , 2011 Litron Laboratories, 2003) .
Statistical analysis of the MNT was done by 1-way ANOVA (2-tailed) using Dunnett's correction for multiple comparisons in GraphPad Prism 6 software.
Pig-a assay. As described previously in Zeller et al. (2016) and in accordance with Rat MutaFlow kit instructions (Litron Laboratories, 2014), Pig-a analyses were performed on blood samples collected on study days 1 (before treatment), 29 and 52. "Precolumn" samples consisted of a small aliquot of each fully labeled and stained sample that was analyzed for approximately 1 min in order to provide % RET measurements as well as RBC to counting bead and RET to counting bead ratios. The majority of each sample was then used for an immunomagnetic separation procedure that utilized Miltenyi MACS LS columns ) and anti-PE microbeads . The resulting 'post-column' eluates were analyzed for approximately 3 min to provide mutant phenotype RBC to counting bead and mutant phenotype RET to counting bead ratios. As described previously, pre-and postcolumn data were used to calculate mutant erythrocyte (RBC CD59À ) and mutant reticulocyte (RET CD59À ) frequencies. For the current study, this typically provided >2 Â 10 6 RET and approximately 150 Â 10 6 RBC equivalents per rat per time point for the evaluation. An Instrument Calibration Standard was generated on each day of data acquisition. As approximately one half of these erythrocytes were not incubated with antiCD59-PE, these samples contained a high prevalence of mutant-mimic cells and provided a means to define the location of GPI anchor-deficient erythrocytes. A Becton-Dickinson flow cytometer running Diva software (BD Biosciences, San Jose, California) was used for Pig-a data acquisition and analysis. No dedicated statistical analysis of Pig-a mutation data was performed, since there was no apparent relevant increase in the mutant frequency of RBC or RET. Statistical analysis for Pig-a was only planned to be done post hoc based on biological plausibility of response.
Comet assay. The standard protocol for sampling of tissues, preparation of a single cell suspension and slides, followed by DNA unwinding, electrophoresis and staining of slides used follows the recommendations given in (Burlinson et al., 2007; Hartmann et al., 2003; JaCVAM, 2013; Tice et al., 2000) . Isolated cells were embedded into agarose on a slide, lysed overnight, followed by alkaline unwinding for 20 min. Electrophoresis was performed at approximately 26 V (corresponding to 1 V/cm), 300 mA for 40 min at approximately 4 C. Coded slides were analyzed by Metafer4/Relosys4 (MetaSystems, Germany). A total of 150 comets per slide were measured. After rejections of artifacts, the median of the first 100 cells per slide was calculated. Two replicates per animal and tissue were analyzed. Hundred cells per replicate were anticipated; however according to OECD 489 (OECD 489, 2014) , a minimum of 75 cells per replicate were considered as valid, which was the case except in a single occasion (indicated in results). The median value of each replicate was calculated for each animal and from these 2 slides the mean value of the dose group was calculated. The number of "clouds" or hedgehogs (a morphology indicative of highly damaged cells often associated with severe cytotoxicity, necrosis, or apoptosis) out of 100 cells was scored manually for each replicate. Generally, comet assay data should be interpreted carefully if the number of hedgehog cells exceed 30%, since an impact of cytotoxicity on the data cannot be excluded (Burlinson, 2007; OECD 489, 2014) . The statistical analysis of the comet assay data was performed by transforming individual %TI values using the arcsine of the square root, and based on this, the median was calculated per slide, followed by calculating the mean per animal across replicates (Zeller et al. 2016) . Linear mixed effects models in combination with polynomial contrasts were used to test treated versus vehicle control groups. In addition, the treatments were compared with the negative control using the Dunnett's test (one sided). The analysis was performed in a PipelinePilot-R (v2.10.1) implementation with the package "nlme" (nonlinear mixed effects model).
Immunohistochemistry and image analysis. Immunohistochemistry (IHC) for c-H2AX and Ki-67 was performed on 2 separate liver sections from all animals on the Ventana Discovery XTTM immunostainer. An antic-H2AX mouse monoclonal antibody (Abcam, ab26350) was used as primary antibody and a biotin-SPconjugated donkey anti-mouse IgG (Jackson ImmunoResearch, 715-065-151) as a secondary antibody. Detection was performed in a standard protocol using the Ventana DAB MapTM kit (760-124). Gamma-H2AX positively stained nuclei showed either one or several positive foci or were diffusely stained.
For Ki-67, a prediluted rabbit monoclonal anti-Ki-67 (30-9, Ventana, 790-4286) was used as a primary antibody and a biotin-SP-conjugated donkey antirabbit IgG (Jackson ImmunoResearch, 711-065-152) as a secondary antibody. Detection was performed in a standard protocol using the Ventana DAB MapTM kit (760-124).
IHC slides were scanned with an Aperio ScanScopeATTM slidescanner and ten 20Â high power fields (HPFs) were randomly selected from the liver scan. Approximately 3 mm 2 of liver tissue were analyzed. Image analysis for the 2 separate IHC stains was performed with a ruleset recognizing c-H2AX and Ki-67 positively stained hepatocyte nuclei using the Definiens TissueStudioTM Version 3.51 software. The average number per mm 2 of c-H2AX positive nuclei was calculated for each animal.
Statistical evaluation was performed for the number of c-H2AX-and Ki-67-positive nuclei per HPF. The dose groups and the solvent controls were compared with each other by KruskalWallis test (2-tailed) with Dunn's correction.
RESULTS
Overall, a dose-dependent decrease in body weight gain of animals treated with 4-CLoT (25-250 mg/kg/day) as compared with the vehicle control was observed over the treatment period of 28 days (Figure 1) . Treatment of animals with 250 mg/kg/day of 4-CloT resulted in an initial slight decrease in body weight up to day 4. In general, all dose groups treated with 4-CloT showed a body weight development that was in parallel to the vehicle group but shifted downwards. During the second treatment period of 3 days (50-350 mg/kg/day) a dose-dependent decrease in body weight development was observed.
We observed some mild clinical signs of toxicity at different dose levels and study days, such as: slight to moderate hypoactivity, salivation, increased digging in sawdust, rooting, and increased grooming. None of the observed effects were judged to critically affect the health condition of the animals but clearly demonstrated that the compound was bioavailable and reached systemic circulation.
Hematology and MetHb
Formation of MetHb has been described as a consequence of the exposure to aromatic amines (Birner and Neumann, 1988; Hjelm and de Verdier, 1965; Purnell and Singh, 2005) . Thus, quantification of MetHb in addition to a complete blood count was performed throughout the study for animals of the high dose groups (150-350 mg/kg/day groups, Figure 2 ). Data sampled on days 23 and 26 were combined (individual animal data showed no considerable differences) a 2-and 3-fold increase of MetHb over concurrent control was observed at 200 and 250 mg/ kg/day, respectively (Figure 2A) . A considerable increase in absolute RET counts was observed on days 23/26 (individual animal data showed no considerable differences and were thus summarized) at 200 and 250 mg/kg/day (Figure 2A) . Interestingly, on day 59, ie, following the second dosing period of 3 days, the RET count of those dose groups was comparable to the concurrent vehicle control group. On day 59, these samples demonstrated a dose-dependent increase in %MetHb with a maximum increase of 12-fold over control at 350 mg/kg/day ( Figure 2B ). Other standard hematology parameters, including Hb, have been evaluated, but did not reveal any effect following the oral administration of 4-CloT to male rats (Supplementary Table 1 ).
Micronucleus test
Blood for the micronucleus test was taken from all animals dosed from 25 to 250 mg/kg/day on day 8 of the study. With the exception of one animal (treated with 150 mg/kg/day) all animals showed a dose-dependent increase in percentage of RET (%RET) (Figs. 3A and 3B ). This is overall in line with observations from the standard hematology analysis made on days 23/26 and 59 ( Figure 2B, Supplementary Table 1 ). In general, the dosedependent increase in the frequency of MN-RET and micronucleated MN-NCE on day 8 were in parallel with the increase in %RET (Figs. 3A and 3B ). The highest individual MN-RET frequency (0.6%) and the highest mean MN-RET frequency (0.4%) were observed for the dose group of 250 mg/kg/day. An individual animal of the vehicle control group showed a considerably (approximately 3-fold over mean controls) higher MN-RET value, exceeding the laboratory's 95% tolerance interval (TI). This animal was therefore excluded from statistical analysis as an outlier. Statistical significance for the induction of MN was reached at doses ! 200 mg/kg/day for both RET and NCE. Moreover, a significant increase in %RET was observed at the same dose levels.
Pig-a assay
The %RET as well as the frequency of Pig-a mutant phenotype cells (ie, RBC CD59À and RET
CD59À
) was evaluated before (day 1 prior to treatment) and after (days 29 and 52) the administration of 4-CloT. As already observed using a different method to identify RET (RNA content vs CD71), a dose-dependent increase in the %RET was observed for animals treated with 4-CloT on day 29 (Figs. 4C and 4D ). In contrast, %RET values on day 52 (Figs. 4E and 4F), ie, following a treatment-free period, were comparable to the concurrent vehicle control animals.
No relevant increase of RBC CD59À or RET CD59À cells was observed on days 29 or 52 following treatment with 4-CloT (Figs. 4C-F) . Overall, values from all animals were comparable to those observed on day 1 of the study and are within the 95% TI of our laboratory's historical range of vehicle controls.
Comet assay
For the evaluation of DNA strand breakage in the comet assay, liver, urinary bladder, jejunum, and peripheral blood were sampled during necropsy on day 59 of the study. Comet assay evaluation in peripheral blood was additionally performed on day 8 of the study (25-250 mg/kg/day). No statistically significant increase in %TI was observed on day 8 (data not shown). In consequence, dose levels for comet assay evaluation were adapted for the second dosing phase on days 56-59 (150-350 mg/kg/day) and animals of the 25 mg/kg/day dose were administered with 350 mg/kg/day. This dose level was chosen based on a previously performed dose range finding experiment (see "Materials and Methods" section). Neither for jejunum nor peripheral blood, any increase in the %TI was observed (Figs. 5C and 5D ). For liver, a statistical significance increase in %TI was reached at ! 150 mg/kg/day, which was however not dose related ( Figure 5A ). Overall, comet assay values and the inter-animal variability decreased with increasing dose levels. However, a high number of hedgehog cells, ie, > 30% (Table 1 ) was observed at all dose levels evaluated for liver. Interestingly, there is no correlation between %TI and the number of hedgehog cells at the individual animal level. No relevant increase in the number of hedgehog cells was observed in any of the other tissues (Table 1) . For the urinary bladder, a dose-dependent increase in %tail intensity was observed and statistical significance was reached at ! 150 mg/kg/day ( Figure 5B ). However, a relatively high variability in %TI for 4-CloT-treated animals was observed and individual %TI values partly overlap with those of vehicle control animals.
Histopathology
Histopathological evaluation of the liver revealed some compound-and dose-related findings. Treatment-related histopathological findings consisted of minimal to marked, centrilobular to diffuse, microvesicular vacuolation at ! 200 mg/kg/day in the liver. This finding was accompanied by minimal centrilobular hepatocellular hypertrophy and reduced cytoplasmic rarefaction indicative of reduced glycogen deposits at ! 250 mg/kg/day. In the urinary bladder, a minimal to moderate subepithelial edema was observed in 5 animals at ! 250 mg/kg/day with no effect on the epithelium. There were no treatment-related histopathological findings in jejunum, kidney, and bone marrow.
Immunohistochemistry (gamma H2aX and Ki-67)
At the end of the study, liver was stained for c-H2AX and Ki-67 by IHC. For both endpoints a considerable increase in the number of positive cells was observed (Figure 6 ), which was however not strictly dose related. IHC was not done for urinary bladder as there was no histopathological finding in the epithelium. Gamma-H2AX positively stained foci or diffusely stained nuclei, indicating DNA double strand breaks or DNA-repair intermediates (Staszewski et al., 2008) , increased statistically significantly >20-fold as compared with control at 250 mg/kg/ day. When 350 mg/kg/day was compared with 250 mg/kg/day, the number of c-H2AX-positive nuclei was decreased (to approximately 10-fold increase over control), which was considered to be due to marked treatment-related, degenerative/toxic liver findings (marked vacuolation) seen in histopathology.
For Ki-67 indicating cell proliferation, a statistically significant increase was observed at 150 and 250 mg/kg/day. The highest response was also observed at 250 mg/kg/day with no strict dose response and a decrease at 350 mg/kg/day. A high variability of values existed in all treatment groups (details see Supplementary Table 4 ). 
DISCUSSION
The potential of 4-CloT to induce DNA damage response in rats was evaluated using various endpoints, tissues and time points. In addition to classical markers of DNA damage, ie, mutation and clastogenicity, evaluation of standard hematology, including MetHb; histopathology of evaluated tissues, ie, liver, urinary bladder and jejunum, and IHC of c-H2AX and Ki-67 was performed.
Following a treatment of animals with 4-CloT on 8 consecutive days, a dose-dependent increase in the frequency of %RET (day 8) was observed and the dose-response relationship was similar to those seen for the MN-RET and MN-NCE (Figure 3) . The observed increase in frequency of micronucleated cells may therefore be confounded by the proliferation of RET (Tweats et al., 2007) . The dose-dependent increase of %RET was confirmed throughout the study by using different methodologies and was reversible following a treatment-free period on day 59 (see Figs. 2 and 4) . A comet assay performed in peripheral blood on day 8 did not show an increase in DNA damage (data not shown), which may further suggest that the observed increase in micronuclei is due to proliferation of RET. In addition, 4-CloT did not induce mutant cells, detectable as CD59-phenotypic RETs or RBCs following 28 days of treatment (days 29 and 52, Figure 4 ). With the exception of a dose-dependent increase of MetHb, other effects on standard hematology parameters were not observed. Since the increase of MetHb was in parallel to the dose-dependent increases of %RET and MN-RET, a causal relationship is assumed. For the comet assay, while no effect was observed in peripheral blood (day 8) and jejunum (day 59, Figure 5 ), a statistically significant increase in %TI was seen in liver and urinary bladder (both day 59, Figure 5 ). Interestingly, for liver no strict dose response was observed but a dose-dependent decrease, in parallel to a decrease in the inter-individual variability. For urinary bladder overall (Figure 5 ), a dose-dependent increase was observed. Although for liver a considerable increase in the frequency of hedgehog cells (>30%) was observed at all dose levels, no such effect was seen in urinary bladder, jejunum, or peripheral blood (Table 1) . As the preparation of the single cell suspension from all tissues was done in a randomized manner, we exclude an experimental impact related to the tissue processing order similar to what we have published earlier for the in vivo comet assay (Struwe et al., 2011) . Histopathological evaluation of liver and urinary bladder showed some treatment related findings. For liver degeneration, cytotoxic lesions such as marked vacuolation and hypertrophy were observed. In urinary bladder, no histopathological changes in the epithelium which is the primary cell type sampled for comet assay evaluation under the described experimental condition were observed. It has previously been described that (cyto)toxic effects may affect comet assay data (Burlinson et al. 2007; Rothfuss et al., 2011; Vasquez, 2012) . Therefore, regulatory guidelines for rodent comet assay (OECD 489, 2014) recommend histopathological evaluation and the determination of hedgehog cells. Individual examples have been published, for which cytotoxicity can lead to an increased, as well as decreased ("hormetic"), dose response (Vasquez, 2012) . The author suggested that prelethal endonuclease activity of damaged cells that occurs in early stages and even before pronounced degenerative histopathological changes, as we observed with vacuolation of hepatocytes, may interfere with comet assay data. For both c-H2AX and Ki-67, stained in liver samples from day 59 (Figure 6 ), an increase in the number of positive nuclei was observed that, similar to the comet assay, was not strictly dose-dependent and even decreased at the highest dose of 350 mg/kg/day. Little is known on the kinetics of these 2 markers in vivo and how they may be impacted by (cyto)toxicity. Nevertheless, nuclear c-H2AX staining has also been described in the context of apoptosis (Ding et al., 2016; Solier and Pommier, 2014) , although histopathological evaluation did not reveal any apoptosis in hepatocytes. Additional experiments evaluating the time course of c-H2AX and Ki-67 induction may be useful to better understand the underlying mechanism.
Based on published data of the (1) genotoxicity and (2) carcinogenicity of 4-CloT, it has been classified by IARC as potential human carcinogen (IARC 2A, IARC, 2010): (1) A variety of experiments, such as unscheduled DNA synthesis in rat hepatocytes, chromosomal aberrations in mammalian cells as well as mutations in the mouse spot test were observed (reviewed by IARC, 2010). In contrast, the majority of bacterial tests with 4-CloT in S. typhimurium did not reveal a mutagenic potential, individual positive responses were observed. In light of this mixed published dataset further in vitro data, such as Ames or micronucleus test in the presence of metabolic activation system may be useful. (2) 4-CloT induced tumors at various sites in mice (hemangiosarcoma, hemangioma, hepatocellular adenoma, and carcinoma; alveolar/bronchiolar adenoma and carcinoma (MAK, 2012) but interestingly not in rats. Bentley et al. (1986a,b) hypothesized that species differences in the metabolic activation may account for the higher susceptibility of mice versus rats. Although a higher amount of the reactive metabolite bound to DNA was detected in mice, more of the formed 4-CloT metabolite was bound to protein in rats, suggesting that those metabolites differ in their affinity towards DNA and proteins. Interestingly, MetHb is reported to be higher in rats than in mice (Birner and Neumann, 1988) . We therefore, plan to perform an evaluation of the DNA damage response pattern in L5178Y cells in the presence of Phenobarbital/b-Naphtoflavon induced rat and mouse liver S9 by using flow cytometry (Bryce et al., 2017) .
In conclusion, 4-CloT showed some effects on the integrity of the DNA as measured by the comet assay in liver and urinary bladder but not in peripheral blood or jejunum. At the same time, histopathological changes and an increase in the frequency of hedgehog cells were seen in liver. An increase in the frequency of micronuclei in peripheral blood was observed in parallel to a dose-dependent increase of RET and MetHb. Therefore, it cannot be excluded that (cyto)toxicity, leading to anemia and subsequent compensatory erythropoiesis, had an impact. Interestingly, no increase in the frequency of RET CD59À and RBC CD59À was observed, suggesting a high robustness of the Pig-a assay towards cytotoxicity. Considerable differences regarding the metabolization and DNA binding of 4-CloT have been demonstrated between mice and rats. Although 4-CloT is tumorigenic in mice, it was not in rats, probably due to species differences in the metabolic activation and DNA binding of the compound. Dedicated experiments (as performed in this study with male rats) in mice would be required to further evaluate species differences.
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